PHARMA FOCUS: VACCINE MANUFACTURING & DISTRIBUTION
Integrated solutions for
sterilisation, freeze-drying and cold storage
Growth in vaccines production, including the SARS-COV-2 vaccine, is fuelling the increased need for sterilisation facilities to manufacture single use medical devices such as plastic syringes. To meet the demand, Telstar has expanded its engineering and manufacturing capacity in process systems, which integrate sterilisation, containment and lyophilisation technologies. TELSTAR LYOBETA – A SMALL-SCALE SOLUTION Specifically designed for labscale formulation, research and development work, the latest LyoBeta innovation developed by Telstar sees the integration of a mobile app which tracks temperature and pressure parameters in real-time, enabling any freeze-drying process parameter or alarm to be monitored remotely.
Telstar has increased its software and controls engineering team as well as established a new 4 500m2 assembly and testing area in line with the growing demand for ethylene oxide sterilisation systems
T
o face the next mediumterm phase in the rollout of global COVID-19 vaccination programmes, Telstar has strengthened the development of its freeze-drying systems for the manufacturing of vaccines under lyophilised form to guarantee their complete and safe distribution. The company’s end-to-end engineering and GMP services are highly specialised. Its integrated solutions cover all phases of vaccine manufacturing, from the development of process equipment and integrated solutions in isolation technology systems to sterilisation and freezedrying applications. Its solid, multidisciplinary team consists of experts in cGMP pharma production processes, cleanroom
46
MAY 2021 // WWW.PHARMACOS.CO.ZA
installations and critical utilities, working alongside customers to provide a comprehensive service throughout the project life cycle. Experienced in turnkey integrated projects for complete pharma manufacturing and process critical installations, Telstar has led numerous complex and unique projects designed to guarantee aseptic and efficient production processes in pharmaceutical and life sciences environments.
NEW AND IMPROVED UPRIGHT FREEZERS Telstar has reinforced the production of Boreas, its -80°C ultra-lowtemperature freezer, to meet vaccine manufacturers’ immediate and increased needs for robust cold chain infrastructure. The company will also
This small-scale solution offers flexibility and performance within the compact footprint often required by laboratories. Its advanced process control features include a PLC-based control system, enhanced control and programming capabilities and management software. These features are said to make LyoBeta the most complete, efficient and convenient pilot unit on the market. double its production of the latest generation of ultra-low-temperature freezers, which comply with the stringent storage requirements set out to protect the integrity of vaccines – not only in the healthcare sector but also in logistics and transport processes. Boreas has been designed to increase the average performance by 20%. An innovative mechanical design enhances its robustness, efficiency and ergonomics as well as ensures the integrity of the cold preservation process. Equipped with vacuum panels, the freezer guarantees the highest level of thermal insulation and maintains a temperature of -80°C with ambient temperatures up to 28°C.
